Sanofi: No proof that vaccine linked to Philippines deaths

February 7, 2018
Credit: National Cancer Institute

Drugmaker Sanofi insists there's no evidence of a link between the world's first dengue vaccine and children's deaths in the Philippines.

Paris-based Sanofi said Wednesday it lost 19 million euros in the fourth quarter on the vaccine as it bought back unused medicines, but doesn't expect further related losses this year.

CEO Olivier Brandicourt called concerns about the vaccine "very worrisome" but said no problems were reported outside the Philippines. He said "we have absolutely no evidence that the vaccine has been linked to any deaths."

Sanofi said in November that the vaccine could put people at risk of severe disease if they hadn't previously been infected.

Philippines authorities say the deaths of three children may have "causal association" to the , and the government wants a refund from Sanofi.

Explore further: Philippines: Three deaths may be linked to dengue vaccinations

Related Stories

Philippines: Three deaths may be linked to dengue vaccinations

February 2, 2018
Philippine health officials said Friday that the deaths of three children injected with a Sanofi Pasteur dengue vaccine may have "causal association" to the inoculation, including two who may have died because the vaccine ...

Philippines probes deaths after dengue vaccine suspended

December 21, 2017
Philippine officials are investigating whether three deaths were linked to an anti-dengue vaccine that the country's regulators have suspended, health officials said Thursday.

Sanofi to reimburse Philippines for unused dengue vaccine (Update)

January 15, 2018
French pharmaceutical giant Sanofi will reimburse the Philippine government for leftover doses of an anti-dengue vaccine whose use was suspended due to health concerns, the two parties said Monday.

Philippines says deaths in vaccine row 'consistent with' dengue

January 11, 2018
The Philippines said Thursday that some of the 14 children who died after receiving a controversial vaccine showed signs of "severe dengue", as investigators probe the drug whose use was suspended due to health concerns.

Philippines probing 14 deaths amid dengue vaccine furore

January 5, 2018
The Philippines is investigating if the deaths of 14 children had any link to a dengue vaccine whose use the government has suspended due to health concerns, officials said Friday.

Sanofi rejects refund demand faces Philippine suit over dengue vaccine (Update)

February 5, 2018
French pharmaceutical giant Sanofi on Monday rejected a Philippine government demand to return tens of millions of dollars paid for a dengue vaccine after the programme was suspended over health concerns.

Recommended for you

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.